# Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

> **NCT05966480** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alumis Inc** · enrollment: 408 (actual)

## Conditions studied

- SLE

## Interventions

- **DRUG:** Envudeucitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05966480
- **Lead sponsor:** Alumis Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-26
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966480, "Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05966480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*